158 related articles for article (PubMed ID: 32161278)
1. Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer.
Larsson AM; Bendahl PO; Aaltonen K; Jansson S; Forsare C; Bergqvist M; Jørgensen CLT; Rydén L
Sci Rep; 2020 Mar; 10(1):4484. PubMed ID: 32161278
[TBL] [Abstract][Full Text] [Related]
2. Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial.
Paoletti C; Barlow WE; Cobain EF; Bergqvist M; Mehta RS; Gralow JR; Hortobagyi GN; Albain KS; Pusztai L; Sharma P; Godwin AK; Thompson AM; Hayes DF; Rae JM
Clin Cancer Res; 2021 Nov; 27(22):6115-6123. PubMed ID: 34521624
[TBL] [Abstract][Full Text] [Related]
3. Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Cabel L; Rosenblum D; Lerebours F; Brain E; Loirat D; Bergqvist M; Cottu P; Donnadieu A; Bethune A; Kiavue N; Rodrigues M; Pierga JY; Tanguy ML; Bidard FC
Breast Cancer Res; 2020 Sep; 22(1):98. PubMed ID: 32928264
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
5. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.
Jagarlamudi KK; Hansson LO; Eriksson S
BMC Cancer; 2015 Feb; 15():66. PubMed ID: 25881026
[TBL] [Abstract][Full Text] [Related]
6. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.
Chen Y; Ying M; Chen Y; Hu M; Lin Y; Chen D; Li X; Zhang M; Yun X; Zhou J; He E; Skog S
Int J Clin Oncol; 2010 Aug; 15(4):359-68. PubMed ID: 20354751
[TBL] [Abstract][Full Text] [Related]
7. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer.
Li HX; Lei DS; Wang XQ; Skog S; He Q
Oncol Rep; 2005 Jan; 13(1):145-9. PubMed ID: 15583816
[TBL] [Abstract][Full Text] [Related]
8. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
[TBL] [Abstract][Full Text] [Related]
9. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial.
Bjöhle J; Bergqvist J; Gronowitz JS; Johansson H; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Söderberg M; Sundquist M; Walz TM; Fernö M; Bergh J; Hatschek T
Breast Cancer Res Treat; 2013 Jun; 139(3):751-8. PubMed ID: 23736998
[TBL] [Abstract][Full Text] [Related]
10. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients.
Zhang J; Jia Q; Zou S; Zhang P; Zhang X; Skog S; Luo P; Zhang W; He Q
Oncol Rep; 2006 Feb; 15(2):455-61. PubMed ID: 16391869
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.
Vernieri C; Milano M; Mennitto A; Maggi C; Ferrari B; Rinaldi L; Mennitto R; Stefanetti C; Re B; Mariani G; Bianchi G; Capri G; de Braud F
Breast Cancer Res Treat; 2017 Sep; 165(2):365-373. PubMed ID: 28616768
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression.
Huang S; Lin J; Guo N; Zhang M; Yun X; Liu S; Zhou J; He E; Skog S
Asian Pac J Cancer Prev; 2011; 12(2):497-505. PubMed ID: 21545220
[TBL] [Abstract][Full Text] [Related]
13. Relationship between thymidine kinase 1 before radiotherapy and prognosis in breast cancer patients with diabetes.
Wang Z; Zhang W; Huo B; Dong L; Zhang J
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32202305
[TBL] [Abstract][Full Text] [Related]
14. Properties of cellular and serum forms of thymidine kinase 1 (TK1) in dogs with acute lymphocytic leukemia (ALL) and canine mammary tumors (CMTs): implications for TK1 as a proliferation biomarker.
Jagarlamudi KK; Westberg S; Rönnberg H; Eriksson S
BMC Vet Res; 2014 Oct; 10():228. PubMed ID: 25293656
[TBL] [Abstract][Full Text] [Related]
15. Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume.
Tribukait B
BMC Cancer; 2020 May; 20(1):440. PubMed ID: 32423477
[TBL] [Abstract][Full Text] [Related]
16. Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer.
Deutsch TM; Riethdorf S; Nees J; Hartkopf AD; Schönfisch B; Domschke C; Sprick MR; Schütz F; Brucker SY; Stefanovic S; Sohn C; Pantel K; Trumpp A; Schneeweiss A; Wallwiener M
Breast Cancer Res Treat; 2016 Nov; 160(2):277-290. PubMed ID: 27696083
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
[TBL] [Abstract][Full Text] [Related]
18. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study.
Visvanathan K; Fackler MS; Zhang Z; Lopez-Bujanda ZA; Jeter SC; Sokoll LJ; Garrett-Mayer E; Cope LM; Umbricht CB; Euhus DM; Forero A; Storniolo AM; Nanda R; Lin NU; Carey LA; Ingle JN; Sukumar S; Wolff AC
J Clin Oncol; 2017 Mar; 35(7):751-758. PubMed ID: 27870562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
